Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis" [0.03%]
关于《信迪利单抗联合贝伐珠单抗治疗EGFR野生型非鳞状细胞非小细胞肺癌的疗效和安全性：随机、双盲、III期临床研究》一文的回复：LAZERTINIB治疗伴中枢神经系统转移的EGFR突变NSCLC：通过荟萃分析强化第三代TKIs的作用
Byoung Chul Cho,YuKyung Kim
Byoung Chul Cho
Response to the letter to the Editor on "The Changing Landscape of Lung Cancer Resection Outcomes Over the Past Two Decades" [0.03%]
关于“过去二十年来肺癌切除术结局变化”的信的回复
Charles-Antoine Guay,Alexandre Suhani,Laurie Perreault et al.
Charles-Antoine Guay et al.
Factors Associated With Provider Decision-Making of Early-Stage Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy or Sublobar Resection [0.03%]
影响早期肺癌患者进行立体定向体放射治疗或亚肺叶切除决策的因素分析
Agostina E Velo,Jeremy Mudd,Christopher G Slatore et al.
Agostina E Velo et al.
Background: Treatment decision-making for early-stage non-small cell lung cancer (NSCLC) in patients who have high-operative risk is complex. Identifying patient factors that influence physicians' choices between sublobar...
Neoadjuvant Chemo-Immunotherapy for Surgically Resectable Non-Small Cell Lung Cancer: Balancing Promise and Pitfalls [0.03%]
可手术非小细胞肺癌的新辅助化疗免疫治疗：把握机遇和挑战
Parth Anil Desai,Hossein Borghaei,Martin J Edelman
Parth Anil Desai
Definitive resection has long anchored curative therapy for early-stage and locally advanced non-small cell lung cancer (NSCLC), with adjuvant platinum doublets-and now adjuvant immune-checkpoint inhibitors (ICIs)-providing incremental gain...
Mehmet Mutlu Çatli,Arif Hakan Önder
Mehmet Mutlu Çatli
Minimally Invasive Surgery Versus SABR in Stage IA NSCLC: Interpreting Real-World Evidence with Caution [0.03%]
小心解读真实世界证据：早诊肺癌的微创手术与立体定向放射治疗的比较
Asim Armagan Aydin,Erkan Kayikcioglu
Asim Armagan Aydin
Letter to the Editor: "Prognostic Implications of Lymph Node Status in Non-Small-Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Study" [0.03%]
论著评论：“新辅助化疗免疫治疗前后非小细胞肺癌患者淋巴结状态的预后影响：一项多中心回顾性研究
Parth Aphale,Shashank Dokania,Himanshu Shekhar
Parth Aphale
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial [0.03%]
针对表皮生长因子变异且MET扩增的晚期非小细胞肺癌患者使用萨沃利替尼联合奥希替尼治疗：一项二期随机临床试验
James Chih-Hsin Yang,Yuh-Min Chen,Ullas Batra et al.
James Chih-Hsin Yang et al.
Background: MET amplification is the most common resistance mechanism to first-line osimertinib. We report safety and efficacy data from a phase II study assessing savolitinib plus osimertinib in epidermal growth factor r...
Brief Report: Lung Cancer Diagnoses among Lung Cancer Screening Program Participants With Family History of Lung Cancer [0.03%]
家族史肺癌患者中肺癌筛查项目参与者的肺癌诊断情况简报
Julia G Katcher,Christine C Shusted,Padmanabh Bhatt et al.
Julia G Katcher et al.